RxDoctor Payments DataLook up a doctor →

Gregg Hallman, MD

Urology · Cape Girardeau, MONPI 1891735890

Payments from drug & device makers

$8,837in general payments, 2019–2025

Across 333 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EDAP Technomed Inc$2K
  • Astellas Pharma US Inc$834
  • Intuitive Surgical$820
  • Dendreon Pharmaceuticals LLC$616
  • Rochester Medical Corporation$472
  • Johnson & Johnson$470
  • plus $4K from 38 others

What the payments were for

  • Travel & lodging$1,21814%
  • Food & beverage$7,35683%
  • Education$120%
  • Entertainment$2513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,837 in reported general payments places this provider in the 75th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$362,255
Medicare patients
804
Services billed
8,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron91$45,508
GemtesaVibegron20$14,886
Tamsulosin Hcl347$3,242
Fesoterodine Fumarate ErFesoterodine Fumarate25$1,863
Trospium Chloride ErTrospium Chloride12$1,636
Trospium Chloride37$1,612
Finasteride96$782
Silodosin13$515
Testosterone Cypionate15$331
Imipramine Hcl15$222
Cephalexin39$191
Amitriptyline Hcl11$132
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$109
Tramadol Hcl54$104
Oxybutynin Chloride ErOxybutynin Chloride15$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$834$45,50891 claims
Sumitomo Pharma America, Inc.Gemtesa$111$14,88620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 250 urology providers in Missouri.

Other urology in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →